NurExone Biologic Inc (TSX-V:NRX) head of corporate communications Inbar Paz-Benayoun speaks to Proactive from the sidelines of the OCTQX Annual Issuers Forum in London. She explains how pursuing an OTC listing fits in with NurExone's corporate strategy and says that company is "really on it" when it comes to developing its product and bringing it to the market.
NurExone pioneering a new non-invasive spinal cord therapy
